Technology
Health
Medical
AtriCure
$28.709876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$28.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.01 (0.03%) Today
+$0.01 (0.03%) Today
Why Robinhood?
You can buy or sell AtriCure and other stocks, options, ETFs, and crypto commission-free!
About
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. Read More It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
Employees
620
Headquarters
Mason, Ohio
Founded
2000
Market Cap
1.11B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
208.77K
High Today
$28.70
Low Today
$28.48
Open Price
$28.68
Volume
2.40K
52 Week High
$36.49
52 Week Low
$19.22
Collections
Technology
Health
Medical
US
North America
News
MarketBeatMar 8
Stock Price, News, & Analysis for AtriCure
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar ...
StreetInsiderMar 4
Axonics Modulation Technologies Inc. (AXNX) Announces Michael H. Carrel to Board
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Michael H. Carrel has been appointed to the Axonics board of directors, effective immediately. Mr. Carrel has served as the president and CEO and member of the board of AtriCure, Inc. (NASDAQ: ATRC) since late 2012. AtriCure is a medical device co...
Price Paid on Robinhood
2% Lower
Right Now
52 Week Low
$19.22
Average Price Paid
$29.29
52 Week High
$36.49
Earnings
-$0.31
-$0.23
-$0.16
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 25, After Hours